nti-Cancer Drug Discovery & Development Conference to Feature New Targets, Clinical Agents, and Technologies on June 12-13 In Princeton, NJ, USA
PRINCETON, N.J., April 14 /PRNewswire/ -- Late-breaking advances in anti-cancer research on novel protein kinase, metalloproteinase, farnesyl transferase, and anti-angiogenic inhibitors at the pre-clinical and clinical stages will be the focus of a new pharma conference series to take place in Princeton, NJ on June 12-13, 2000, announces Strategic Research Institute.
The meeting, divided into four discrete sections, 1) identifying new targets, 2) novel anti-tumor agents, 3) protein kinase inhibitors, and 4) anti-angiogenic inhibitors will feature as speakers prominent pharmaceutical, biotechnology, and academic scientists revealing their newest findings.
Presenting papers on behalf of the industry will be Hoffmann-La Roche, Merck, Schering Plough, Bristol-Myers Squibb, Parke-Davis, Genentech, Glaxo Wellcome, GD Searle, Sugen, Isis Pharmaceuticals, Imclone Systems, British Biotech and Cell Pathways, while NCI, Duke University Medical Center, Georgetown University, and Columbia University will represent the academic community.
Dr. Gary Gordon of Searle will present the company's compelling findings on COX-2's implication in familial adenomatous polyposis.
I. Bernard Weinstein, MD, of Columbia University, will present a new paper entitled "Disorders in Cell Circuitry in Cancer: Exploitable Targets for Prevention and Therapy."
To receive the full agenda and/or register for the conference, please contact Jon Liong of Strategic Research Institute at jliong@srinstitute.com or 212-967-0095, x243 (please include name, corporate affiliation, mailing address, and fax number.)
For information on the exposition, please contact Mark Alexay at malexay@hotmail.com. |
